ProQR tests IPO threshold

While investors typically see preclinical companies as being too early for the public markets, a few examples from the current IPO window hint that Dutch cystic fibrosis play ProQR Therapeutics B.V. could be another exception to the rule. The combination of strong private investors and the company's focus on a hot space should help attract buysiders.

Last week, ProQR set terms for its IPO on NASDAQ, proposing to sell 6.3 million shares at $11-$13. At $12, the company would raise $75 million and be valued at $251.6 million...